Study finds that hepatitis C in the U.S. could become 'rare' within 20 years


Researchers using a computer model say that hepatitis C could become "rare" — affecting no more than 1 in 1,500 people — in the United States by 2036.
Right now, roughly 1 in 100 people have hepatitis C in the U.S., but newer medicines and expanded screenings for adults born between 1945 and 1965 could make the number drop. A study conducted by Jagpreet Chhatwal of The University of Texas MC Anderson Cancer Center in Houston and colleagues modeled the effect the medicines and screenings will have on hepatitis C, and found that it would become rare by 2036, and could even reach that goal by 2026 if there were stricter guidelines for screenings.
The researchers wrote in Annals of Internal Medicine that the screening regimen now would identify close to 487,000 cases of hepatitis C infection within the next 10 years, and using current conditions, 124,200 cases of liver cirrhosis, 78,800 cases of liver cancer, 126,500 liver-related deaths, and 9,900 liver transplants could be prevented by 2050.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
"We were pleasantly surprised that in the next 22 years we could make this a rare disease," Chhatwal told Reuters.
Hepatitis C is a viral infection of the liver that, if left untreated, can lead to liver damage, liver failure, and cancer. The researchers say it costs $6.5 billion a year to care for the 3.2 million people in the United States with hepatitis C.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Catherine Garcia has worked as a senior writer at The Week since 2014. Her writing and reporting have appeared in Entertainment Weekly, The New York Times, Wirecutter, NBC News and "The Book of Jezebel," among others. She's a graduate of the University of Redlands and the Columbia University Graduate School of Journalism.
-
Helsinki's year of zero road fatalities
Under the Radar Finland's 'Vision Zero' safety strategy 'shifts responsibility for crashes from road users to the designers of the road system'
-
Critics' choice: Outstanding new Japanese restaurants
Feature An all-women sushi team, a 15-seat listening bar, and more
-
Why do Dana White and Donald Trump keep pushing for a White House UFC match?
TODAY'S BIG QUESTION The president and the sports mogul each have their own reasons for wanting a White House spectacle
-
RFK Jr. shuts down mRNA vaccine funding at agency
Speed Read The decision canceled or modified 22 projects, primarily for work on vaccines and therapeutics for respiratory viruses
-
Measles cases surge to 33-year high
Speed Read The infection was declared eliminated from the US in 2000 but has seen a resurgence amid vaccine hesitancy
-
Kennedy's vaccine panel signals skepticism, change
Speed Read RFK Jr.'s new vaccine advisory board intends to make changes to the decades-old US immunization system
-
Kennedy ousts entire CDC vaccine advisory panel
speed read Health Secretary RFK Jr. is a longtime anti-vaccine activist who has criticized the panel of experts
-
RFK Jr. scraps Covid shots for pregnant women, kids
Speed Read The Health Secretary announced a policy change without informing CDC officials
-
New FDA chiefs limit Covid-19 shots to elderly, sick
speed read The FDA set stricter approval standards for booster shots
-
US overdose deaths plunged 27% last year
speed read Drug overdose still 'remains the leading cause of death for Americans aged 18-44,' said the CDC
-
Trump seeks to cut drug prices via executive order
speed read The president's order tells pharmaceutical companies to lower prescription drug prices, but it will likely be thrown out by the courts